Zeke Capital Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Zeke Capital Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$1.27M	Sell	31,313 -3,414	-10%	-$181K	0.08%	115
2022 Q3	$2.27M	Hold	34,727	–	–	0.17%	64
2022 Q2	$2.11M	Buy	34,727 +4,614	+15%	+$271K	0.14%	72
2022 Q1	$1.89M	Buy	30,113 +6,180	+26%	+$388K	0.1%	97
2021 Q4	$1.81M	Buy	23,933 +10,804	+82%	+$944K	0.11%	63
2021 Q3	$1.47M	Sell	13,129 -526	-4%	-$66.1K	0.08%	77
2021 Q2	$2.21M	Buy	+13,655	New	+$1.66M	0.14%	63

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Zeke Capital Advisors's CRSP Position: Q4 2022 in Review

Zeke Capital Advisors reduced its CRISPR Therapeutics (CRSP) stake by 9.8% in Q4 2022, selling an estimated $181K and leaving 31,313 shares worth $1.27M. The position accounts for 0.08% of the portfolio, ranked #115.

Zeke Capital Advisors first reported a position in CRSP in Q2 2021 and has held it in 7 quarters since. The position peaked at $2.27M in Q3 2022. 398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

Zeke Capital Advisors held 31,313 shares of CRISPR Therapeutics worth $1.27M as of Q4 2022.
Zeke Capital Advisors sold 3,414 CRISPR Therapeutics shares in Q4 2022, an estimated $181K.
CRISPR Therapeutics made up 0.08% of Zeke Capital Advisors's portfolio in Q4 2022, its #115 holding.
Zeke Capital Advisors first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 7 quarters since.
Zeke Capital Advisors's CRISPR Therapeutics position peaked at $2.27M in Q3 2022.
398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on Zeke Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.